{'fraction_non_alphanumeric': 0.05606617647058824, 'fraction_numerical': 0.04963235294117647, 'mean_word_length': 4.918478260869565, 'pattern_counts': {'":': 0, '<': 2, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
The effect of thyroxine‐suppressive therapy in patients with solitary non‐toxic thyroid nodules – a randomised, double‐blind, placebo‐controlled study

The efficacy of thyroxine (T4) for solitary non‐toxic thyroid nodule remains uncertain. In this study, 60 patients with solitary non‐toxic thyroid nodule were divided randomly into two groups. Group I (n = 30) received thyroxine 100 µg/day for 6 months and group II (n = 30) received placebo. The volume of the thyroid nodules in 11 patients decreased more than 50% after thyroxine therapy (36.7%, responders). In these 11 patients, the mean serum thyroglobulin level decreased significantly (340 ± 115 to 162 ± 86 µg/l, p < 0.01). Compared with the non‐responders (n = 19, 63.3%), the serum thyroglobulin level before treatment was significantly higher (340 ± 115 vs. 220 ± 102 µg/l, p < 0.05). Thyroxine‐suppressive therapy is proved as a useful tool in reducing nodule size in some patients with solitary thyroid nodules. The patients with a higher serum thyroglobulin level generally respond better to thyroxine‐suppressive therapy.